Soledad Bárez-López1,2, Maria Jesus Obregon1, Raquel Martínez-de-Mena1, Juan Bernal1,2, Ana Guadaño-Ferraz1,2, Beatriz Morte1,2. 1. 1 Department of Endocrine and Nervous System Pathophysiology, Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM), Madrid, Spain . 2. 2 Department of Endocrine, U-708, Center for Biomedical Research on Rare Diseases (Ciberer) , Instituto de Salud Carlos III, Madrid, Spain .
Abstract
BACKGROUND: Monocarboxylate transporter 8 (MCT8) is a thyroid hormone-specific cell membrane transporter. Mutations in the MCT8 gene lead to profound psychomotor retardation and abnormal thyroid hormone serum levels with low thyroxine (T4) and high triiodothyronine (T3). Currently, therapeutic options for patients are limited. Triiodothyroacetic acid (TRIAC) has potential therapeutic value. The aim of this study was to evaluate the effects and efficacy of therapeutic doses of TRIAC on Mct8-deficient mice (Mct8KO). METHODS: Wild-type (Wt) and Mct8KO mice were treated with 30 ng TRIAC/g of body weight/day, given in drinking water, from postnatal day 21 to 30. TRIAC, T4 and T3 levels in plasma, as well as T3 and TRIAC content in the cerebral cortex and striatum were measured by specific radioimmunoassays. The activities of deiodinases 1 and 2 were measured in liver and cortex. The effect of TRIAC treatment in the expression of T3-dependent genes was measured in the heart, cerebral cortex, and striatum. RESULTS: Plasma TRIAC concentration were the same in Wt and Mct8KO animals after treatment. TRIAC treatment greatly decreased plasma T4 in Wt and Mct8KO mice, and reduced T3 to normal levels in the Mct8KO mice. Deiodinase 1 activity and gene expression in the liver increased, while it did not have any effect on the expression of Serca2a in the heart. TRIAC treatment did not induce the expression of T3-dependent genes in the cerebral cortex or striatum, but further decreased expression of Flywch2 in the cortex and Aldh1a1 and Flywch2 in the striatum. Direct measurements of TRIAC and T3 content in the cortex and striatum revealed a decrease in T3 after treatment with no significant increase in the level of endogenous TRIAC. CONCLUSIONS: Therapeutic doses of TRIAC in Mct8KO mice restored plasma T3 levels but severely decreased T4 levels. TRIAC has a direct effect on deiodinase 1 in the liver and does not have an effect on gene expression in the heart. The increase in the plasma TRIAC levels after treatment is not sufficient to increase TRIAC levels in the brain and to promote the expression of T3-dependent genes in brain cells. Instead, it leads to a state of brain hypothyroidism with reduced T3 content.
BACKGROUND:Monocarboxylate transporter 8 (MCT8) is a thyroid hormone-specific cell membrane transporter. Mutations in the MCT8 gene lead to profound psychomotor retardation and abnormal thyroid hormone serum levels with low thyroxine (T4) and high triiodothyronine (T3). Currently, therapeutic options for patients are limited. Triiodothyroacetic acid (TRIAC) has potential therapeutic value. The aim of this study was to evaluate the effects and efficacy of therapeutic doses of TRIAC on Mct8-deficientmice (Mct8KO). METHODS: Wild-type (Wt) and Mct8KO mice were treated with 30 ng TRIAC/g of body weight/day, given in drinking water, from postnatal day 21 to 30. TRIAC, T4 and T3 levels in plasma, as well as T3 and TRIAC content in the cerebral cortex and striatum were measured by specific radioimmunoassays. The activities of deiodinases 1 and 2 were measured in liver and cortex. The effect of TRIAC treatment in the expression of T3-dependent genes was measured in the heart, cerebral cortex, and striatum. RESULTS: Plasma TRIAC concentration were the same in Wt and Mct8KO animals after treatment. TRIAC treatment greatly decreased plasma T4 in Wt and Mct8KO mice, and reduced T3 to normal levels in the Mct8KO mice. Deiodinase 1 activity and gene expression in the liver increased, while it did not have any effect on the expression of Serca2a in the heart. TRIAC treatment did not induce the expression of T3-dependent genes in the cerebral cortex or striatum, but further decreased expression of Flywch2 in the cortex and Aldh1a1 and Flywch2 in the striatum. Direct measurements of TRIAC and T3 content in the cortex and striatum revealed a decrease in T3 after treatment with no significant increase in the level of endogenous TRIAC. CONCLUSIONS: Therapeutic doses of TRIAC in Mct8KO mice restored plasma T3 levels but severely decreased T4 levels. TRIAC has a direct effect on deiodinase 1 in the liver and does not have an effect on gene expression in the heart. The increase in the plasma TRIAC levels after treatment is not sufficient to increase TRIAC levels in the brain and to promote the expression of T3-dependent genes in brain cells. Instead, it leads to a state of brain hypothyroidism with reduced T3 content.
Authors: Soledad Bárez-López; Meredith D Hartley; Carmen Grijota-Martínez; Thomas S Scanlan; Ana Guadaño-Ferraz Journal: Thyroid Date: 2018-06-29 Impact factor: 6.568
Authors: Soledad Bárez-López; Carmen Grijota-Martínez; Xiao-Hui Liao; Samuel Refetoff; Ana Guadaño-Ferraz Journal: PLoS One Date: 2019-12-06 Impact factor: 3.240
Authors: Rahimeh Emamnejad; Mary Dass; Michael Mahlis; Salome Bozkurt; Sining Ye; Maurice Pagnin; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos Journal: Front Pharmacol Date: 2022-09-05 Impact factor: 5.988
Authors: Stefan Groeneweg; Robin P Peeters; Carla Moran; Athanasia Stoupa; Françoise Auriol; Davide Tonduti; Alice Dica; Laura Paone; Klara Rozenkova; Jana Malikova; Adri van der Walt; Irenaeus F M de Coo; Anne McGowan; Greta Lyons; Femke K Aarsen; Diana Barca; Ingrid M van Beynum; Marieke M van der Knoop; Jurgen Jansen; Martien Manshande; Roelineke J Lunsing; Stan Nowak; Corstiaan A den Uil; M Carola Zillikens; Frank E Visser; Paul Vrijmoeth; Marie Claire Y de Wit; Nicole I Wolf; Angelique Zandstra; Gautam Ambegaonkar; Yogen Singh; Yolanda B de Rijke; Marco Medici; Enrico S Bertini; Sylvia Depoorter; Jan Lebl; Marco Cappa; Linda De Meirleir; Heiko Krude; Dana Craiu; Federica Zibordi; Isabelle Oliver Petit; Michel Polak; Krishna Chatterjee; Theo J Visser; W Edward Visser Journal: Lancet Diabetes Endocrinol Date: 2019-07-31 Impact factor: 32.069
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; David Gómez-Andrés; Ana Guadaño-Ferraz Journal: Front Neurosci Date: 2020-04-28 Impact factor: 4.677